Cancer Genetics and Epigenetics 2024, Vol.12, No.2, 97-105 http://medscipublisher.com/index.php/cge 104 Brönimann S., Pradere B., Karakiewicz P., Abufaraj M., Briganti A., and Shariat S.F., 2020, An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer, Expert Review of Molecular Diagnostics, 20(8): 841-850. https://doi.org/10.1080/14737159.2020.1785288 Carter H.B., Helfand B., Mamawala M., Wu Y., Landis P., Yu H., Yu H., Wiley K., Na R., Na R., Shi Z., Shi Z., Petkewicz J., Shah S., Fantus R., Fantus R., Novakovic K., Brendler C., Zheng S., Isaacs W., Xu J., and Xu J., 2019, Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer, European Urology, 75(5): 743-749. https://doi.org/10.1016/j.eururo.2018.09.021 Casanova-Salas I., Athie A., Boutros P.C., Del Re M., Miyamoto D.T., Pienta K.J., Posadas E., Sowalsky A., Stenzl A., Wyatt A., and Mateo J., 2021, Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer, European Urology, 79(6): 762-771. https://doi.org/10.1016/j.eururo.2020.12.037 Chen M., and Zhao H., 2019, Next-generation sequencing in liquid biopsy: cancer screening and early detection, Human Genomics, 13(1): 34. https://doi.org/10.1186/s40246-019-0220-8 Chi K.N., Barnicle A., Sibilla C., Lai Z., Corcoran C., Barrett J.C., Adelman C., Qiu P., Easter A., Dearden S., Oxnard G., Agarwal N., Azad A., Bono J., Mateo J., Olmos D., Thiery-Vuillemin A., and Harrington E. A., 2023, Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound, Clinical Cancer Research, 29(1): 81-91. https://doi.org/10.1158/1078-0432.CCR-22-0931 Choudhury A.D., Eeles R., Freedland S.J., Isaacs W.B., Pomerantz M.M., Schalken J.A., Tammela T., and Visakorpi T., 2012, The role of genetic markers in the management of prostate cancer, European Urology, 62(4): 577-587. https://doi.org/10.1016/j.eururo.2012.05.054 Costa V.L., Henrique R., and Jerónimo C., 2007, Epigenetic markers for molecular detection of prostate cancer, Disease Markers, 23(1-2): 31-41. https://doi.org/10.1155/2007/356742 Cozar J.M., Robles-Fernandez I., Martinez-Gonzalez L.J., Pascual-Geler M., Rodriguez-Martinez A., Serrano M.J., Lorente J., and Alvarez-Cubero M.J., 2018, Genetic markers a landscape in prostate cancer, Mutation Research/Reviews in Mutation Research, 775: 1-10. https://doi.org/10.1016/j.mrrev.2017.11.004 Cucchiara V., Cooperberg M.R., Dall'Era M., Lin D.W., Montorsi F., Schalken J.A., and Evans C.P., 2018, Genomic markers in prostate cancer decision making, European Urology, 73(4): 572-582. https://doi.org/10.1016/j.eururo.2017.10.036 Cui M., Gao X.S., Gu X., Guo W., Li X., Ma M., Qin S., Qi X., Xie M., Peng C., and Bai Y., 2017, BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer, Oncotarget, 8(25): 40222. https://doi.org/10.18632/oncotarget.16712 Cyll K., Ersvær E., Vlatkovic L., Pradhan M., Kildal W., Avranden Kjær M., Kleppe A., Hveem T., Carlsen B., Gill S., Löffeler S., Haug E., Wæhre H., Sooriakumaran P., and Danielsen H.E., 2017, Tumour heterogeneity poses a significant challenge to cancer biomarker research, British Journal of Cancer, 117(3): 367-375. https://doi.org/10.1038/bjc.2017.171 Das S., Salami S.S., Spratt D.E., Kaffenberger S.D., Jacobs M.F., and Morgan T.M., 2019, Bringing prostate cancer germline genetics into clinical practice, Journal of Urology, 202(2): 223-230. https://doi.org/10.1097/JU.0000000000000137 Downes M.R., Byrne J.C., Pennington S.R., Dunn M.J., Fitzpatrick J.M., and Watson R.W.G., 2007, Urinary markers for prostate cancer, BJU International, 99(2): 263-268. https://doi.org/10.1111/j.1464-410X.2006.06610.x Hughes L., Zhu F., Ross E., Gross L., Uzzo R.G., Chen D.Y., Viterbo R., Rebbeck T., and Giri V.N., 2012, Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection, Cancer Epidemiology, Biomarkers and Prevention, 21(1): 53-60. https://doi.org/10.1158/1055-9965.EPI-11-0727 Kader A.K., Sun J., Reck B.H., Newcombe P.J., Kim S.T., Hsu F.C., D'Agostino R., Tao S., Zhang Z., Turner A., Platek G., Spraggs C., Whittaker J., Lane B., Isaacs W., Meyers D., Bleecker E., Torti F., Trent J., Mcconnell J., Zheng S., Condreay L., Rittmaster R., and Xu J., 2012, Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial, European Urology, 62(6): 953-961. https://doi.org/10.1016/j.eururo.2012.05.006 Lynch H.T., Kosoko‐Lasaki O., Leslie S.W., Rendell M., Shaw T., Snyder C., D'Agostino R., Tao S., Zhang Z., Turner A., Platek G., Spraggs C., Whittaker J., Lane B., Isaacs W., Meyers D., Bleecker E., Torti F., Trent J., Mcconnell J., Zheng S., Condreay L., Rittmaster R., and Powell I., 2016, Screening for familial and hereditary prostate cancer, International Journal of Cancer, 138(11): 2579-2591. https://doi.org/10.1002/ijc.29949 Manson-Bahr D., Ball R., Gundem G., Sethia K., Mills R., Rochester M., Goody V., Anderson E., O'meara S., Flather M., Keeling M., Yazbek-Hanna M., Hurst R., Curley H., Clark J., Brewer D., McDermott U., and Cooper C., 2015, Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing, Journal of Clinical Pathology, 68(3): 212-217. https://doi.org/10.1136/jclinpath-2014-202754
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==